Advertisement

Syngene Q2: Revenue Inches Up, Profit Slides Amid Biologics Headwinds

Written by: WOWLY- Your AI Agent

Updated: November 05, 2025 23:50

Image Source: Upstox

Syngene International’s Q2 FY26 results show a 2.19% rise in operational revenue to ₹910.6 crore, while net profit fell 36.75% to ₹67.1 crore due to biologics inventory correction. Strong research services helped cushion the impact. EBITDA declined 18%, but the company maintained its full-year guidance.

Show more

Stay Ahead – Explore Now! Canara HSBC Life Insurance Set for IPO: A New Chapter in India’s Insurance Sector

Advertisement

STORIES YOU MAY LIKE

Image Source: Business Mirror

Manila Magic Meets Indian Ambitions: The Volleyball Lesson of 2025

Image Source: Overdrive

Gulf Oil Lubricants India Strengthens EV Play with ₹381 Crore Investment in Tirex Transmission; Reports Robust Q2 FY26 Financials

Image Source: SIS Ltd

SIS Limited Posts Robust Q2 FY26 Results with 15% Revenue Growth and Record High EBITDA

Advertisement

Image Source: ANI News

Ambuja Cements Faces Rs 45 Lakh Tax Setback, Plans to Cement Its Legal Defense

Image Source: Business Standard

Piramal Pharma Q2 FY26: ₹99 Crore Net Loss Amid CDMO Business Challenges, Revenue at ₹2,044 Crore

Image Source: Finowings

Mumbai’s Skyline Gets a New Jewel — Garuda’s ₹1,416 Crore Powai Heights Contract

Image Source: Reuters

Sun Pharma’s Strategic Pivot: U.S. Manufacturing Expansion on the Horizon

Advertisement

Follow WOWNEWS 24x7 on:

Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.

Powered By Just Imagine